Nuvo Life Health: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://nuvolifehealth.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.

1. 1

   “The following claims concerning compounded semaglutide and tirzepatide products appear on your website:”

2. 2

   “• “Semaglutide Injection (similar to Ozempic and Wegovy)” • “Tirzepatide (similar to Mounjaro)””

3. 3

   “Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].”

1. 1

   Letter issued

   September 2025

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

nuvolifehealth.com resolved on 2026-08-09 but served a Sedo domain-parking page — the template titled "nuvolifehealth.com - nuvolifehealth Resources and Information.", carrying the Sedo parking logo and an ad script, with no storefront behind it. A parked or listed domain is not evidence a business has closed: it can be un-parked, and a company can trade under a different domain. Recorded as unknown rather than ceased-operations.

Where a claim sits changes how hard it is to escape. A sentence in a FAQ can be read sceptically, or skipped. A parenthesis inside the product's own name cannot: it is what appears in the search result, on the listing, in the cart, on the confirmation email and next to the charge on the card statement. "Semaglutide Injection (similar to Ozempic and Wegovy)" is doing the job of a product title, and the job of a product title is to tell you what the thing IS. The hedge does not save it either — "similar to" is softer than "generic", but a shopper does not weigh adjectives while buying; they take the parenthesis as the explanation of what they are getting, which is precisely the point FDA made about it. The concrete habit: when the brand name is inside the product name, treat it as advertising rather than description, and go looking for the two things a title never carries — who compounded it, and what strength and formulation you are actually being sent. The site is not trading behind that domain today. The letter makes no finding about the products' quality or contents, and has not been closed out.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Nuvo Life Health failed to respond.